Form 4: Alkermes EVP Exercises RSUs, Sells Shares for Tax

Alkermes plc's EVP and Chief Legal Officer, David Joseph Gaffin, exercised restricted stock units and sold a portion of the resulting shares to cover tax obligations.

Summary

• David Joseph Gaffin, Executive Vice President and Chief Legal Officer of Alkermes, Inc., engaged in transactions involving Alkermes plc Ordinary Shares.
• On August 3, 2025, Gaffin acquired 2,014 Ordinary Shares through the exercise of a Restricted Stock Unit Award.
• Concurrently, Gaffin disposed of 895 Ordinary Shares at a price of $26.55 per share.
• The disposition of shares was likely to cover tax liabilities associated with the RSU exercise, indicated by transaction code 'F'.
• Following these transactions, Gaffin's direct beneficial ownership of Ordinary Shares is 205,374.
• The Restricted Stock Unit Award vests in four equal annual installments, commencing on August 3, 2023.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing reports a routine executive compensation event (RSU vesting and tax-related sale). It's not a discretionary sale indicating lack of confidence, but rather a standard part of compensation. The executive still holds a significant number of shares.

Positives

• The exercise of Restricted Stock Units indicates the vesting and conversion of equity compensation, which is a standard component of executive remuneration.
• The sale of shares to cover tax obligations (Transaction Code F) is a routine and expected event following RSU vesting, and does not necessarily signal a negative outlook for the company.

Negatives

• A portion of the shares (895) were sold, resulting in a slight reduction in the executive's direct beneficial ownership after the exercise and sale.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report for an executive at a pharmaceutical company. It reflects standard equity compensation practices within the industry, where executives receive restricted stock units that vest over time, and a portion are often sold upon vesting to cover tax liabilities.

Comparison to Industry Standards

• The utilization of Restricted Stock Units (RSUs) as a form of executive compensation is a prevalent practice across the pharmaceutical and biotechnology industries, aligning with global benchmarks for incentivizing long-term executive performance.
• The disposition of shares to cover tax withholding (Transaction Code F) is a standard and expected event when RSUs vest and convert into shares, observed widely among executives in publicly traded companies.

Stakeholder Impact

• Shareholders: Minimal direct impact. The transaction is a routine part of executive compensation and does not signal a change in company fundamentals or strategy. The sale of a small number of shares for tax purposes is not typically viewed as a negative signal.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine transaction where an executive exercised restricted stock units and sold a portion to cover tax liabilities. This is a standard compensation event and does not indicate a change in the company's fundamentals or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

Alkermes, ALKS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, David Joseph Gaffin, Share Sale, Equity Compensation